Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations
about
Using fractional polynomials to model the effect of cumulative duration of exposure on outcomes: applications to cohort and nested case-control designs.The backlash against bioequivalence and the interchangeability of brand-name and generic drugs.Incidence and pattern of thyroid dysfunction in patients on chronic amiodarone therapy: experience at a tertiary care centre in oman.Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).Pharmacokinetics and Bioequivalence of Branded and Generic Formulations of Dofetilide 0.5-mg Capsules After Single-Dose Administration in Healthy Subjects.
P2860
Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations
@ast
Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations
@en
type
label
Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations
@ast
Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations
@en
prefLabel
Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations
@ast
Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations
@en
P2093
P2860
P356
P1476
Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations
@en
P2093
Cynthia A Jackevicius
Elham Rahme
Hassan Behlouli
Jennifer Joo
Karin H Humphries
Mark J Eisenberg
Meytal A Tsadok
Vidal Essebag
P2860
P304
P356
10.1503/CMAJ.101800
P407
P577
2011-07-11T00:00:00Z